. 2011 Jan 19;12(1):69–76. doi: 10.1007/s10195-010-0125-8

Table 4.

Dosage and time of administration of available new oral anticoagulants (NOA)

Active principle	Brand name	Dosage and time of administration
Dabigatran^a (antifactor IIa)	Pradaxa^®	110 mg 1–4 h after surgery, then 220 mg/day If age > 75 years or creatinine clearance 30–50 ml/min or amiodarone intake, 75 mg 1–4 h after surgery, then 150 mg/day
Rivaroxaban^b (antifactor Xa)	Xarelto^®	10 mg 6–10 h after surgery, then 10 mg/day

Active principle

Brand name

Dosage and time of administration

Dabigatran^a

(antifactor IIa)

Pradaxa^®

110 mg 1–4 h after surgery, then 220 mg/day

If age > 75 years or creatinine clearance 30–50 ml/min or amiodarone intake, 75 mg 1–4 h after surgery, then 150 mg/day

Rivaroxaban^b

(antifactor Xa)

Xarelto^®

10 mg 6–10 h after surgery, then 10 mg/day

^aDabigatran has proved not to be inferior to low-molecular-weight heparin (LMWH) both in terms of efficacy and safety. As concerns dabigatran, in the literature, there is no information available on patients undergoing regional anaesthesia [11, 12]

^bRivaroxaban has shown to have greater efficacy than LMWH, with overlapping safety [13–16]. An analysis performed after publication of rivaroxaban registration study confirmed its safety in patients undergoing neuraxial anesthesia